InnoSIGN

InnoSIGN is a precision medicine company that transforms complex multi-omics data into actionable, easy-to-interpret insights. Utilizing a proprietary algorithm, its platform identifies the true drivers of disease, thereby accelerating drug discovery and improving treatment selection. The technology is universally applicable across various diseases, supporting the entire drug development continuum from preclinical stages to companion diagnostics (CDx) and commercial launch. The company commercializes its proprietary mRNA-based OncoSIGNal pathway activity profiling technology, revolutionizing precision medicine by providing deeper insights into disease mechanisms.